Vanda V. West-Ward: This Time, Dosage Adjustment Claims Are Patent Eligible Subject Matter | Latest News RSS feed

Vanda V. West-Ward: This Time, Dosage Adjustment Claims Are Patent Eligible Subject Matter - Latest News

Vanda v. West-Ward: This Time, Dosage Adjustment Claims are Patent Eligible Subject Matter

“Generic drug manufacturers accused of infringement should fully appreciate the subjective nature of a § 101 defense when evaluating their litigation risk.” The Federal Circuit’s decision in Vanda Pha... read more

Vanda on Rehearing: Will the Federal Circuit Defy SCOTUS?

Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd., 887 F ... What the majority suggests, but does not say, is that Mayo’s claims would be patent eligible if they added one more step of injecting the ... read more

Applicability of §101 Challenges in ANDA Pharmaceutical Litigation

By utilizing §101 motions less than 2 percent of the time ... to make these claims patent-eligible subject matter, and the court granted the motion to dismiss. Id. at 11. In contrast, Judge Sleet in V... read more

Looking for another news?

Avadel Pharmaceuticals plc (AVDL)

patents and proprietary rights associated with the Drug may not provide adequate protection; patents licensed to us under our license agreement with Serenity that cover the Drug are subject to litigat... read more

Mayo/Alice ‘Directed to’ Inquiry and a Split Federal Circuit: Vanda Pharma v. West-Ward Pharma

In these decisions, the court found claims patent eligible ... for subject matter eligibility, it is of interest to see how these decisions are influencing the outcome of patent eligibility disputes. ... read more

Interim Results

The study read-out is planned for 2018 with a planned submission in 2019 On 22 November the Group announced a further strengthening of its existing partnership with Hikma (through its wholly owned sub... read more

Eligibility: Preamble Does the Trick for Federal Circuit

The claims require personalized dosage — depending upon the patient’s metabolization rate of iloperidone (“CYP2D6 activity”). West-Ward filed an Abbreviated ... transform the claim to a patent eligibl... read more

Avadel Pharmaceuticals plc (AVDL)

On June 2, 2017, Avadel Pharmaceuticals plc (the "Company") furnished to the holders of its ... of shareholders which is scheduled to be held at 12:00 Noon (Irish Standard Time) on Wednesday, June 28, ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us